Peak Expiratory Flow (PEF) Predicted Calculator

About

Peak Expiratory Flow (PEF) is the maximum flow rate generated during a forced expiration from total lung capacity, measured in liters per minute. It was first described by Hadorn in 1943 and later popularized by Wright in 1959 with the development of the Wright peak flow meter. PEF is a key component of asthma monitoring and management, recommended by the Global Initiative for Asthma (GINA) for home monitoring in patients with moderate to severe asthma. Predicted values are calculated using regression equations derived from population-based studies, with the most commonly used being the Nunn and Gregg equations (1989) for adults and the NHANES III equations for diverse ethnic populations. PEF monitoring is integrated into asthma action plans using a three-zone system: Green Zone (PEF ≥80% of predicted or personal best — asthma is well controlled), Yellow Zone (PEF 50–79% — caution, asthma is worsening), and Red Zone (PEF <50% — medical alert, severe exacerbation requiring immediate treatment). Home PEF monitoring has been shown to improve asthma outcomes, including reduced exacerbations, fewer emergency department visits, and improved quality of life. However, PEF is effort-dependent and requires correct technique for reproducible results. It also has limitations compared to spirometry — FEV₁ is more sensitive for detecting mild airflow obstruction, and PEF may underestimate obstruction in the presence of small airways disease. Despite these limitations, PEF remains a practical and cost-effective tool for home monitoring. Evidence level: Grade B, supported by GINA recommendations and multiple randomized controlled trials.

Formula

Predicted PEF based on age, gender, and height using Nunn & Gregg regression equations for adults.

The Nunn and Gregg equations (BMJ 1989) were derived from a study of over 22,000 healthy adults in the UK. They are gender-specific regression models incorporating age and height. For men, the equations vary by age decade because lung function declines at different rates across the lifespan. For women, separate coefficients are used. The general form is: Predicted PEF = a + (b × age) + (c × height) where a, b, and c are gender-specific constants derived from the regression analysis. For example, a 35-year-old woman who is 165 cm tall would have a predicted PEF calculated based on the female-specific coefficients for her age group. To interpret the result, the measured PEF is expressed as a percentage of the predicted value: % Predicted = (Measured PEF ÷ Predicted PEF) × 100. This percentage determines the asthma zone: ≥80% Green (well-controlled), 50–79% Yellow (caution, worsening asthma), and <50% Red (severe exacerbation). The patient's personal best PEF (measured when asthma is well controlled) is superior to predicted values for creating individualized action plans. However, predicted values are essential as initial reference points, especially for patients newly diagnosed or who have not established a personal best. When using the % predicted, clinicians should note that different reference equations may give different predicted values for the same individual. The NHANES III equations provide race-specific predictions for Caucasian, African American, and Mexican American populations. For optimal accuracy, the reference equation used should match the patient's demographic characteristics.

Score Interpretation

The PEF is a simple, reproducible measure of airway obstruction that plays a central role in asthma management. The Global Initiative for Asthma (GINA) guidelines recommend PEF monitoring for patients with moderate to severe asthma, those with poor perception of airflow limitation, and those who have had life-threatening exacerbations. Home PEF monitoring with a written three-zone action plan has been shown in randomized trials to reduce emergency department visits by up to 40%, hospitalizations by 30%, and nocturnal awakenings. The British Thoracic Society (BTS)/SIGN guidelines similarly endorse peak flow monitoring as part of personalized asthma action plans. PEF is also used in the occupational setting for diagnosing occupational asthma — serial PEF monitoring at work and away from work shows characteristic patterns of work-related deterioration. In the emergency department, PEF measurement is standard for assessing acute asthma severity and response to bronchodilator therapy. A PEF <33% of predicted indicates a life-threatening exacerbation requiring immediate intensive care referral according to BTS guidelines. PEF is also used for asthma diagnosis in primary care — a 20% diurnal variability (difference between morning and evening PEF) over 2–3 weeks suggests a diagnosis of asthma. Beyond asthma, PEF monitoring plays a role in assessing response to COPD treatment, though FEV₁ by spirometry remains the preferred measure. Importantly, PEF should not be used alone to diagnose asthma — it should be combined with symptoms assessment, bronchodilator reversibility testing, and where available, spirometry. PEF has limitations: it is effort-dependent, can miss small airways obstruction, and may underdiagnose asthma severity in patients with good expiratory muscle strength. Despite these limitations, PEF remains the most practical tool for home lung function monitoring worldwide.

Reference Ranges